ADVERSE O
REACTIONS O
The O
following O
were O
adverse O
events O
considered O
to O
be O
drug O
related O
and O
occurring O
with O
a O
frequency O
of O
> O
=1 O
% O
with O
Carac O
: O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
94.6 O
% O
) O
, O
and O
eye B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
( O
5.4 O
% O
) O
. O

The O
signs O
and O
symptoms O
of O
facial B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
( O
i.e. O
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
are O
presented O
below O
. O

Summary O
of O
Facial B-OSE_Labeled_AE
Irritation O
Signs O
and O
Symptoms O
- O
Pooled O
Phase O
3 O
Studies O
Clinical O
Sign O
or O
Symptom O
Active O
1 O
Week O
N=85 O
Active O
2 O
Week O
N=87 O
Active O
4 O
Week O
N=85 O
ALL O
Active O
Treatments O
N=257 O
Vehicle O
Treatments O
N=127 O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
Erythema I-OSE_Labeled_AE
76 O
( O
89.4 O
) O
82 O
( O
94.3 O
) O
82 O
( O
96.5 O
) O
240 O
( O
93.4 O
) O
76 O
( O
59.8 O
) O
Dryness O
59 O
( O
69.4 O
) O
76 O
( O
87.4 O
) O
79 O
( O
92.9 O
) O
214 O
( O
83.3 O
) O
60 O
( O
47.2 O
) O
Burning O
51 O
( O
60.0 O
) O
70 O
( O
80.5 O
) O
71 O
( O
83.5 O
) O
192 O
( O
74.7 O
) O
28 O
( O
22.0 O
) O
Erosion O
21 O
( O
24.7 O
) O
38 O
( O
43.7 O
) O
54 O
( O
63.5 O
) O
113 O
( O
44.0 O
) O
17 O
( O
13.4 O
) O
Pain O
26 O
( O
30.6 O
) O
34 O
( O
39.1 O
) O
52 O
( O
61.2 O
) O
112 O
( O
43.6 O
) O
7 O
( O
5.5 O
) O
Edema O
12 O
( O
14.1 O
) O
28 O
( O
32.2 O
) O
51 O
( O
60.0 O
) O
91 O
( O
35.4 O
) O
6 O
( O
4.7 O
) O
During O
clinical O
trials O
, O
irritation B-OSE_Labeled_AE
generally O
began O
on O
Day O
4 O
and O
persisted O
for O
the O
remainder O
of O
treatment O
. O

Severity O
of O
facial I-OSE_Labeled_AE
irritation O
at O
the O
last O
treatment O
visit O
was O
slightly O
below O
baseline O
for O
the O
vehicle O
group O
, O
mild O
to O
moderate O
for O
the O
1-week O
active O
treatment O
group O
, O
and O
moderate O
for O
the O
2- O
and O
4-week O
active O
treatment O
groups O
. O

Mean O
severity O
declined O
rapidly O
for O
each O
active O
group O
after O
completion O
of O
treatment O
and O
was O
below O
baseline O
for O
each O
group O
at O
the O
Week O
2 O
post-treatment O
follow-up O
visit O
. O

Thirty-one O
patients O
( O
12 O
% O
of O
those O
treated O
with O
Carac O
in O
the O
Phase O
3 O
clinical O
studies O
) O
discontinued O
study O
treatment O
early O
due O
to O
facial B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
. O

Except O
for O
three O
patients O
, O
discontinuation O
of O
treatment O
occurred O
on O
or O
after O
Day O
11 O
of O
treatment O
. O

Eye B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
adverse O
events O
, O
described O
as O
mild O
to O
moderate O
in O
intensity O
, O
were O
characterized O
as O
burning O
, O
watering O
, O
sensitivity O
, O
stinging O
, O
and O
itching O
. O

These O
adverse O
events O
occurred O
across O
all O
treatment O
arms O
in O
one O
of O
the O
two O
Phase O
3 O
studies O
. O

Summary O
of O
All O
Adverse O
Events O
Reported O
in O
> O
=1 O
% O
of O
Patients O
in O
the O
Combined O
Active O
Treatment O
and O
Vehicle O
Groups O
- O
Pooled O
Phase O
3 O
Studies O
9721 O
and O
9722 O
Combined O
Adverse O
Event O
Active O
1 O
Week O
N= O
85 O
Active O
2Week O
N= O
87 O
Active O
4Week O
N= O
85 O
ALL O
Active O
Treatments O
N=257 O
Vehicle O
Treatments O
N=127 O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
BODY B-NonOSE_AE
AS I-NonOSE_AE
A I-NonOSE_AE
WHOLE I-NonOSE_AE
7 O
( O
8.2 O
) O
6 O
( O
6.9 O
) O
12 O
( O
14.1 O
) O
25 O
( O
9.7 O
) O
15 O
( O
11.8 O
) O
Headache B-OSE_Labeled_AE
3 O
( O
3.5 O
) O
2 O
( O
2.3 O
) O
3 O
( O
3.5 O
) O
8 O
( O
3.1 O
) O
3 O
( O
2.4 O
) O
Common B-OSE_Labeled_AE
Cold I-OSE_Labeled_AE
4 O
( O
4.7 O
) O
0 O
2 O
( O
2.4 O
) O
6 O
( O
2.3 O
) O
3 O
( O
2.4 O
) O
Allergy B-OSE_Labeled_AE
0 O
2 O
( O
2.3 O
) O
1 O
( O
1.2 O
) O
3 O
( O
1.2 O
) O
2 O
( O
1.6 O
) O
Infection B-OSE_Labeled_AE
UpperRespiratory I-OSE_Labeled_AE
0 O
0 O
0 O
0 O
2 O
( O
1.6 O
) O
MUSCULOSKELETAL B-NonOSE_AE
1 O
( O
1.2 O
) O
1 O
( O
1.1 O
) O
1 O
( O
1.2 O
) O
3 O
( O
1.2 O
) O
5 O
( O
3.9 O
) O
Muscle B-OSE_Labeled_AE
Soreness I-OSE_Labeled_AE
0 O
0 O
0 O
0 O
2 O
( O
1.6 O
) O
RESPIRATORY B-NonOSE_AE
5 O
( O
5.9 O
) O
0 O
1 O
( O
1.2 O
) O
6 O
( O
2.3 O
) O
6 O
( O
4.7 O
) O
Sinusitis B-OSE_Labeled_AE
4 O
( O
4.7 O
) O
0 O
0 O
4 O
( O
1.6 O
) O
2 O
( O
1.6 O
) O
SKIN B-NonOSE_AE
& I-NonOSE_AE
APPENDAGES I-NonOSE_AE
78 O
( O
91.8 O
) O
83 O
( O
95.4 O
) O
82 O
( O
96.5 O
) O
243 O
( O
94.6 O
) O
85 O
( O
66.9 O
) O
Application B-OSE_Labeled_AE
SiteReaction I-OSE_Labeled_AE
78 O
( O
91.8 O
) O
83 O
( O
95.4 O
) O
82 O
( O
96.5 O
) O
243 O
( O
94.6 O
) O
83 O
( O
65.4 O
) O
Irritation B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
1 O
( O
1.2 O
) O
0 O
2 O
( O
2.4 O
) O
3 O
( O
1.2 O
) O
0 O
SPECIAL B-NonOSE_AE
SENSES I-NonOSE_AE
6 O
( O
7.1 O
) O
4 O
( O
4.6 O
) O
6 O
( O
7.1 O
) O
16 O
( O
6.2 O
) O
6 O
( O
4.7 O
) O
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
5 O
( O
5.9 O
) O
3 O
( O
3.4 O
) O
6 O
( O
7.1 O
) O
14 O
( O
5.4 O
) O
3 O
( O
2.4 O
) O
Adverse O
Experiences O
Reported O
by O
Body O
System O
: O
In O
the O
Phase O
3 O
studies O
, O
no O
serious O
adverse O
event O
was O
considered O
related O
to O
study O
drug O
. O

A O
total O
of O
five O
patients O
, O
three O
in O
the O
active O
treatment O
groups O
and O
two O
in O
the O
vehicle O
group O
, O
experienced O
at O
least O
one O
serious O
adverse O
event O
. O

Three O
patients O
died B-NonOSE_AE
as O
a O
result O
of O
adverse O
event O
( O
s O
) O
considered O
unrelated O
to O
study O
drug O
( O
stomach B-NonOSE_AE
cancer I-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
) O
. O

Post-treatment O
clinical O
laboratory O
tests O
other O
than O
pregnancy B-NonOSE_AE
tests O
were O
not O
performed O
during O
the O
Phase O
3 O
clinical O
studies O
. O

Clinical O
laboratory O
tests O
were O
performed O
during O
conduct O
of O
a O
Phase O
2 O
study O
of O
104 O
patients O
and O
21 O
patients O
in O
a O
Phase O
1 O
study O
. O

No O
abnormal O
serum O
chemistry O
, O
hematology O
, O
or O
urinalysis O
results O
in O
these O
studies O
were O
considered O
clinically O
significant O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Valeant O
Pharmaceuticals O
North O
America O
LLC O
at O
1-800-321-4576 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

